Processing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces completion of the four-week tie-in period for the Media Luna Project ("Media Luna") and first production of precious metal-rich copper concentrate.Jody Kuzenko, President and CEO of Torex, stated:"Following almost three years t ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

Torex Gold Reports Year-End 2024 Reserves & ResourcesDrilling success continues to support reserve life extensionsMarch 19, 2025 6:00 PM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to report year-end 2024 mineral reserves and resources for the Morelos Complex, which includes the producing El Limón Guajes ("ELG ...

10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or ...

Torex Gold Reports Excellent Drill Results from Media Luna West and Initial Results from Media Luna EastCompelling results return multiple high-grade intercepts at both Media Luna East and WestFebruary 24, 2025 6:00 AM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - February 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide results from the ongoing drilling ...

Core Insights - 10x Genomics announced new product innovations to enhance its leadership in single cell and spatial biology, aiming to support high-performance research at scale [1][2] - The company revealed a comprehensive product roadmap for its Visium and Xenium portfolios, focusing on advancements in spatial biology technology [1][3] Single Cell Innovations - The upcoming plate-based workflows for Chromium GEM-X Flex will allow researchers to process over 700 samples in a single run, recovering approximately 1 million cells from a single lane and 8 million cells per chip [3][5] - 10x Cloud Analysis for Large Studies will introduce batch analysis features for managing large datasets, enabling hundreds or thousands of analyses to run in parallel [3][5] - Recent innovations aim to democratize access to single cell analysis by providing high performance at low costs, including GEM-X Flex Gene Expression at one cent per cell and GEM-X Universal Multiplex for approximately $600 per sample [5][6] Spatial Biology Advancements - The Visium HD product launched in 2024 significantly increased resolution and is now compatible with various tissue types, enhancing sensitivity and sequencing efficiency [7][9] - Planned additions to the Visium HD platform include the Visium HD 3' assay for whole transcriptome spatial profiling and Visium HD Cell Segmentation for improved spatial transcriptomics data resolution [9][10] - The Xenium RNA+Protein Multiomics will enable simultaneous detection of RNA and proteins, enhancing multiomic insights into cellular functions [7][9] Company Events and Engagement - 10x Genomics will host a workshop at the AGBT meeting to share the latest developments and data across its platforms, with a live-stream option for remote participants [2][8] - The company is actively showcasing its technologies through scientific presentations and events at AGBT, emphasizing its role in driving biological discovery [8][11]

Torex Gold Reports Q4 and Full Year 2024 Results2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025February 19, 2025 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the t ...

On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).The single-cell and spatial biology company reported quarterly sales of $165.02 million, down 10% year over year, beating the consensus of $159.39 million.Gross margin was 67% for the fourth quarter of 2024 compared to 63% a year ago, primarily due to product mix changes.10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million f ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Can ...

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this life science technology company would post a loss of $0.34 per share when it actually produced a loss of $0.30, delivering a surprise of 11.76%.Over the last four quarters, the co ...